as 07-26-2024 4:00pm EST
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Founded: | 2004 | Country: | United States |
Employees: | N/A | City: | RAMSEY |
Market Cap: | 2.5B | IPO Year: | N/A |
Target Price: | $12.25 | AVG Volume (30 days): | 3.4M |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.02 | EPS Growth: | N/A |
52 Week Low/High: | $3.06 - $14.03 | Next Earning Date: | 08-07-2024 |
Revenue: | $283,176,466 | Revenue Growth: | 55.68% |
Revenue Growth (this year): | 41.22% | Revenue Growth (next year): | 15.94% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Grossman Adam S | ADMA | President,CEO, and Interim CFO | Jun 14 '24 | Sell | $10.72 | 100,000 | $1,071,980.00 | 2,081,475 | SEC Form 4 |
ELMS STEVE | ADMA | Director | Mar 18 '24 | Sell | $6.01 | 49,887 | $299,820.87 | 2,527,500 | SEC Form 4 |
ELMS STEVE | ADMA | Director | Mar 18 '24 | Sell | $6.08 | 411,829 | $2,503,920.32 | 2,115,671 | SEC Form 4 |
ELMS STEVE | ADMA | Director | Mar 13 '24 | Sell | $6.21 | 407,000 | $2,527,470.00 | 3,208,671 | SEC Form 4 |
ELMS STEVE | ADMA | Director | Mar 13 '24 | Sell | $6.05 | 448,276 | $2,712,069.80 | 2,760,395 | SEC Form 4 |
ELMS STEVE | ADMA | Director | Mar 13 '24 | Sell | $6.01 | 183,008 | $1,099,878.08 | 2,577,387 | SEC Form 4 |
ADMA Breaking Stock News: Dive into ADMA Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Zacks
a day ago
Zacks
2 days ago
Zacks
4 days ago
Zacks
8 days ago
Zacks
9 days ago
Simply Wall St.
14 days ago
Zacks
17 days ago
The information presented on this page, "ADMA ADMA Biologics Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.